ZBTB33 Knockout cell line (22Rv1)

Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.

ZBTB33 (zinc finger and BTB domain containing 33) encodes a transcriptional regulator with bimodal DNA-binding specificity for methylated and non-methylated DNA sequences. The protein contains an N-terminal BTB domain and C-terminal zinc fingers and recruits the N-CoR corepressor complex to promote histone deacetylation and repressive chromatin formation. ZBTB33 can regulate transcription of target genes, including genes associated with Wnt signaling, through interactions with corepressor and catenin proteins.

22Rv1 is a human prostate carcinoma epithelial cell line derived from the CWR22R xenograft, which was serially propagated in nude mice after castration-induced regression and relapse of the parental androgen-dependent CWR22 tumor. The cells express prostate-specific antigen (PSA) and retain androgen receptor expression, with growth weakly stimulated by dihydrotestosterone. 22Rv1 cells are tumorigenic in nude mice and are widely used as a model for studying castration-resistant prostate cancer, androgen receptor signaling, tumor progression, and therapeutic responses.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.